Related Experiment Video
Updated: Aug 11, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
A pilot study of a ketogenic diet in patients with Lafora body disease
Simonetta Cardinali1, Laura Canafoglia, Simona Bertoli
1Department of Child Neuropsychiatry, Child EEG Unit, Foundation C. Mondino Institute of Neurology Via Mondino 2, 27100 Pavia, Italy.
Purpose:
Lafora body disease (LBD) is severe and rapidly worsening progressive myoclonus epilepsy (PME), not treatable with specific therapy. In LBD patients, typical polyglucosan accumulations result from alterations of proteins involved in the regulation of glycogen metabolism. Thus, a ketogenic regimen might reasonably be expected to counteract the disease progression. We set out to assess the feasibility and tolerability of a long-term ketogenic diet (KD) in LBD patients and to make a preliminary evaluation of its effect on the disease course.
Methods:
We treated five LBD patients with KD and evaluated the changes in the clinical, neuropsychological and neurophysiological findings over 10-30 months.
Results:
The KD was well tolerated in all the patients for the first 16 months. Nutritional measures and laboratory findings remained substantially stable. The disease progressed in all the patients, reaching an advanced stage in one. Electrophysiological findings indicated the presence of increased cortical excitability in four patients, paralleling the worsening of the myoclonus.
Conclusion:
KD was unable to stop the disease progression. However, given the considerable heterogeneity of the natural history of LBD, we cannot exclude the possibility that KD has the potential to slow down the disease progression. The application of this nutritional approach should be further evaluated in larger case series.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:03In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Related Concept Videos
Lysosomal Hydrolases
Diabetic Ketoacidosis ll: Pathophysiology